337 related articles for article (PubMed ID: 17034468)
1. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
Quirk C; Gebauer K; Owens M; Stampone P
Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
3. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
4. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
Quirk C; Gebauer K; De'Ambrosis B; Slade HB; Meng TC
Cutis; 2010 Jun; 85(6):318-24. PubMed ID: 20666194
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
7. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Maus J; Munzel U
Eur J Dermatol; 2008; 18(6):677-82. PubMed ID: 18955210
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
[TBL] [Abstract][Full Text] [Related]
10. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
11. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma.
Ezughah FI; Dawe RS; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(2):111-7. PubMed ID: 17917935
[TBL] [Abstract][Full Text] [Related]
12. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
13. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
14. 5% imiquimod cream for the treatment of large superficial basal cell carcinoma.
Shumack S; Gebauer K; Quirk C; Macdonald K; Walters SA; Owens M
Arch Dermatol; 2004 Oct; 140(10):1286-7. PubMed ID: 15492202
[No Abstract] [Full Text] [Related]
15. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
17. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study.
Vun Y; Siller G
Australas J Dermatol; 2006 Aug; 47(3):169-71. PubMed ID: 16866996
[TBL] [Abstract][Full Text] [Related]
18. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.
Stockfleth E; Sterry W; Carey-Yard M; Bichel J
Br J Dermatol; 2007 Dec; 157 Suppl 2():41-6. PubMed ID: 18067631
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
Geisse JK; Rich P; Pandya A; Gross K; Andres K; Ginkel A; Owens M
J Am Acad Dermatol; 2002 Sep; 47(3):390-8. PubMed ID: 12196749
[TBL] [Abstract][Full Text] [Related]
20. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
